Duopharma Biotech Berhad Full Year 2023 Earnings: EPS: RM0.055 (vs RM0.074 in FY 2022)

Duopharma Biotech Berhad (KLSE:DPHARMA) Full Year 2023 Results

Key Financial Results

• Revenue: RM704.7m (up 1.1% from FY 2022).
• Net income: RM52.6m (down 25% from FY 2022).
• Profit margin: 7.5% (down from 10% in FY 2022). The decrease in margin was driven by higher expenses.
• EPS: RM0.055 (down from RM0.074 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Duopharma Biotech Berhad Earnings Insights

Looking ahead, revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.

Performance of the market in Malaysia.

The company's shares are down 5.6% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Duopharma Biotech Berhad (at least 1 which is concerning), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.